\
&
Contact us
\
&
Contact us
Published on | 7 months ago
ProgrammesThe European Commission is looking for independent experts to join its AI Scientific Panel. This initiative aims to ensure that Europe leads in the responsible and ethical use of artificial intelligence.
The European Commission has launched a call for experts to join its AI Scientific Panel, which will advise on the implementation of the EU's AI strategy. The panel will focus on ethical and trustworthy AI, supporting research and fostering collaboration across sectors. Interested candidates can apply through the EU's official portal. This initiative underscores the EU's commitment to harnessing AI responsibly while promoting innovation.
Key details include:
For more information, visit the official announcement. Interesting for researchers and AI professionals interested in ethics and policy, as they are the primary stakeholders in the responsible development and deployment of AI technologies.
When applying, please inform us so we can keep track of (and support) applications from Flanders.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space Cybersecurity
On 28 January 2026, the SECURE project has launched a first round of financial support measures to help small businesses achieve compliance with new cybersecurity requirements for their hardware and software products. This will allow micro, small and medium enterprises (MSMEs) to request co-funding to strengthen the cybersecurity of their hardware... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
